Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David O Bates

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Pharmaceuticals (Basel, Switzerland)|January 26, 2024
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in <i>Opisthorchis viverrini</i>-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROSJinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, et al.
Comprehensive Physiology|July 7, 2018
Physiological Role of Vascular Endothelial Growth Factors as Homeostatic RegulatorsDavid O Bates, Nicholas Beazley-Long, Andrew V Benest, et al.
Nature Medicine|November 3, 2014
An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery diseaseRyosuke Kikuchi, Kazuto Nakamura, Susan MacLauchlan, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2017
Differential Expression of VEGF-A<sub>xxx</sub> Isoforms Is Critical for Development of Pulmonary FibrosisShaney L Barratt, Thomas Blythe, Caroline Jarrett, et al.
ACS Chemical Biology|January 31, 2017
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye DiseaseJennifer Batson, Hamish D Toop, Clara Redondo, et al.
Frontiers in Oncology|December 25, 2023
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinomaKyaw Zwar Myint, Mireia Sueca-Comes, Pamela Collier, et al.
Chemical Science|July 24, 2012
Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoformsJeanette Woolard, William Vousden, Steven J Moss, et al.
Cancer Research and Treatment|October 19, 2020
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma CellsBoonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, et al.
Nano Research|August 30, 2016
Direct detection and measurement of wall shear stress using a filamentous bio-nanoparticleDaniela P Lobo, Alan M Wemyss, David J Smith, et al.
Diabetes|November 4, 2018
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic NephropathyKaren L Onions, Monica Gamez, Nicola R Buckner, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Pharmaceuticals (Basel, Switzerland)|January 26, 2024
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in <i>Opisthorchis viverrini</i>-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROSJinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, et al.
Comprehensive Physiology|July 7, 2018
Physiological Role of Vascular Endothelial Growth Factors as Homeostatic RegulatorsDavid O Bates, Nicholas Beazley-Long, Andrew V Benest, et al.
Nature Medicine|November 3, 2014
An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery diseaseRyosuke Kikuchi, Kazuto Nakamura, Susan MacLauchlan, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2017
Differential Expression of VEGF-A<sub>xxx</sub> Isoforms Is Critical for Development of Pulmonary FibrosisShaney L Barratt, Thomas Blythe, Caroline Jarrett, et al.
ACS Chemical Biology|January 31, 2017
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye DiseaseJennifer Batson, Hamish D Toop, Clara Redondo, et al.
Frontiers in Oncology|December 25, 2023
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinomaKyaw Zwar Myint, Mireia Sueca-Comes, Pamela Collier, et al.
Chemical Science|July 24, 2012
Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoformsJeanette Woolard, William Vousden, Steven J Moss, et al.
Cancer Research and Treatment|October 19, 2020
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma CellsBoonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, et al.
Nano Research|August 30, 2016
Direct detection and measurement of wall shear stress using a filamentous bio-nanoparticleDaniela P Lobo, Alan M Wemyss, David J Smith, et al.
Diabetes|November 4, 2018
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic NephropathyKaren L Onions, Monica Gamez, Nicola R Buckner, et al.
Pageof 16